PharmiWeb

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...
PharmiWeb

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update ...
PharmiWeb

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer

Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients ...
PharmiWeb

Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB

MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has ...